Anixa Biosciences, Inc., a clinical-stage biotechnology company specializing in cancer treatment and prevention, has announced the issuance of a new U.S. patent for its chimeric antigen receptor-T cell (CAR-T) technology. Granted by the United States Patent and Trademark Office (USPTO) as Patent Number 12,384,826, the protection now extends until 2045, covering key methods and compositions that underpin Anixa’s innovative CAR-T approach.
The company’s CAR-T platform is specifically engineered to tackle the long-standing hurdles of applying CAR-T therapies to solid tumors, an area where conventional CAR-T treatments have faced limitations. This latest patent builds on Anixa’s expanding intellectual property portfolio, safeguarding the platform’s potential use across a wide range of tumor types. The technology was originally developed by The Wistar Institute and is exclusively licensed to Anixa, which is currently testing it in a clinical trial at Moffitt Cancer Center for the treatment of recurrent ovarian cancer.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, emphasized the strategic importance of the development, noting that the strengthened patent protection is a crucial step in ensuring the clinical and commercial success of the company’s CAR-T program.
Anixa’s therapeutic pipeline includes an ovarian cancer immunotherapy developed in collaboration with Moffitt, utilizing a unique variant called chimeric endocrine receptor-T cell (CER-T) technology. Unlike traditional CAR-T therapies, CER-T uses the natural ligand of the FSHR receptor—FSH—rather than an antibody fragment to target tumor cells. Beyond CAR-T, Anixa is also advancing a portfolio of cancer vaccines in partnership with Cleveland Clinic aimed at preventing and treating breast, ovarian, lung, colon, and prostate cancers by targeting “retired” proteins expressed in certain malignancies.
By partnering with leading research institutions such as The Wistar Institute, Moffitt Cancer Center, and Cleveland Clinic, Anixa leverages cutting-edge scientific advances to develop breakthrough immunotherapies, reinforcing its position as a key innovator in oncology.
